companydata.dkcompanydata.dk

Vericel Denmark ApS: Financial statements 2024

CVR: 19740986

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

Vericel Denmark ApS (CVR 19740986) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -109,464 and a net result of DKK -109,464 compared with DKK -115,548 the year before. Equity in the 2024 report amounted to DKK 6,369,816. The solvency ratio was 99.6%.

Gross Profit
DKK -109,464
Profit/Loss
DKK -109,464
Equity
DKK 6,369,816
Total Assets
DKK 6,396,645
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024--109 t.-109 t.6.4 mio.0
2023--116 t.-116 t.6.5 mio.0
2022--122 t.-122 t.6.6 mio.0
2021--122 t.-122 t.6.7 mio.0
2020--83 t.-83 t.6.8 mio.0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Vericel Denmark ApS: The 2023 annual report is outMar 8, 2024

Vericel Denmark ApS has published its annual report for 2023. Gross profit came to DKK -115,548, and the net result was DKK -115,548.

About Vericel Denmark ApS

Vericel Denmark ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 1996. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named AASTROM BIOSCIENCES DK ApS and GENZYME BIOSURGERY ApS. The management consists of Joseph Anthony Mara Jr. The company is owned by Vericel Corporation. The company has 0 employees (2015). In 2025, the company reported a gross profit of DKK -128,481 and a net result of DKK -128,481 compared with DKK -109,464 the year before. Equity in the 2025 report amounted to DKK 6,241,335.

Source: annual report 2025, Danish Business Authority